Background
first-ever, Stroke, first-ever ischemic stroke, stroke, hemorrhagic, ischemic stroke, acute coronary syndromes, long-term disability, acute stroke, strokes
STROKE, STROKE, ISCHEMIC STROKE, ACUTE CORONARY SYNDROMES, HEART ATTACK, ACUTE STROKE, COMPLICATIONS, STROKES
Stroke is one of the leading causes of long-term disability. It is the second most typical cause of mortality globally. The burden of stroke is much higher in developing countries, accounting for 66% of worldwide strokes [rt-PA is still the only approved treatment for acute stroke. Nevertheless, its accessibility is still low in not only developing countries but also high-income countries due to derangements in supply chains related to war and lack of materials. For this reason, there is an ongoing need for using a loading dose of new antiplatelet agents, which may provide better results for acute stroke patients who are ineligible for rt-PA  [Ticagrelor is a new antiplatelet medication that acts by reversible blockade of the P2Y12 subtype of adenosine diphosphate (ADP) receptor. It was approved by the US Food and Drug Administration (FDA) as a treatment for acute coronary syndromes in 2011, and in 2015, it received approval as a maintenance treatment in patients with a history of a heart attack [Our trial differs from other ticagrelor studies as it focused on comparing the safety and efficacy of ticagrelor versus aspirin within the first 9 h of a first-ever ischemic stroke by assessing the early change in NIHSS after 2 days and 1 week and the change in mRS after 1 week and 3 months, we started the antiplatelet treatment within 9 h of onset, as the ischemic penumbra may remain viable for up to 12 h [Along with the current clinical trial, the efficacy and safety of 180-mg loading dose of ticagrelor administered within 9 h of first-ever ischemic stroke compared to aspirin were assessed through NIHSS, mRS, duration of hospital stay, and possible hemorrhagic complications.